Lovetrue, B. The AI-Discovered Aetiology of COVID-19 and Rationale of the Irinotecan+ Etoposide Combination Therapy for Critically Ill COVID-19 Patients. Medical Hypotheses, 2020, 144, 110180. https://doi.org/10.1016/j.mehy.2020.110180.
Lovetrue, B. The AI-Discovered Aetiology of COVID-19 and Rationale of the Irinotecan+ Etoposide Combination Therapy for Critically Ill COVID-19 Patients. Medical Hypotheses, 2020, 144, 110180. https://doi.org/10.1016/j.mehy.2020.110180.
Lovetrue, B. The AI-Discovered Aetiology of COVID-19 and Rationale of the Irinotecan+ Etoposide Combination Therapy for Critically Ill COVID-19 Patients. Medical Hypotheses, 2020, 144, 110180. https://doi.org/10.1016/j.mehy.2020.110180.
Lovetrue, B. The AI-Discovered Aetiology of COVID-19 and Rationale of the Irinotecan+ Etoposide Combination Therapy for Critically Ill COVID-19 Patients. Medical Hypotheses, 2020, 144, 110180. https://doi.org/10.1016/j.mehy.2020.110180.
Abstract
We present the AI-discovered aetiology of COVID-19, based on a precise disease model of COVID-19 built under five weeks that best matches the epidemiological characteristics, transmission dynamics, clinical features, and biological properties of COVID-19 and consistently explains the rapidly expanding COVID-19 literature. We present that SARS-CoV-2 implements a unique unbiased survival strategy of balancing viral replication with viral spread by increasing its dependence on (i) ACE2-expressing cells for viral entry and spread, (ii) PI3K signaling in ACE2-expressing cells for viral replication and egress, and (iii) viral-non-structural-and-accessory-protein-dependent immunomodulation to balance viral spread and viral replication. We further propose the combination of irinotecan (an in-market topoisomerase I inhibitor) and etoposide (an in-market topoisomerase IIinhibitor) could potentially be an exceptionally effective treatment to protect critically ill patients from death causedby COVID-19-specific cytokine storms triggered by sepsis, ARDS, and other fatal comorbidities.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received:
14 April 2020
Commenter:
Namnama P. Villarta-De Dios
The commenter has declared there is no conflict of interests.
Comment:
Hi. I am interested in the possible benefit of etoposide in the management of cytokine storm among COVID-19 patients. I am part of a group (University of the Philippines College of Medicine) evaluating the literature on anything related to the pandemic. May I ask about the clinical trial you mentioned in the article -- has it commenced? Do you have a writeup on that? Would like to read that as well.
Commenter: Namnama P. Villarta-De Dios
The commenter has declared there is no conflict of interests.
Kind regards,
Nama De Dios